These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
175 related items for PubMed ID: 10354989
1. [Immunotherapy of multiple sclerosis. Consensus and controversies]. Hohlfeld R. Nervenarzt; 1999 Apr; 70(4):297. PubMed ID: 10354989 [No Abstract] [Full Text] [Related]
2. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Petkau J, White R. Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643 [No Abstract] [Full Text] [Related]
3. Treatment of multiple sclerosis with interferon beta-1 b. Abdul-Ahad A, Shah S, Galazka A. Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626 [No Abstract] [Full Text] [Related]
4. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug. Longthorne PN. BMJ; 1996 Nov 16; 313(7067):1263. PubMed ID: 8939141 [No Abstract] [Full Text] [Related]
7. Multiple sclerosis and interferon beta-1b, past, present and future. Horowski R. Clin Neurol Neurosurg; 2002 Jul 09; 104(3):259-64. PubMed ID: 12127665 [No Abstract] [Full Text] [Related]
8. Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease. Chellingsworth M. BMJ; 1996 Nov 16; 313(7067):1263. PubMed ID: 8939140 [No Abstract] [Full Text] [Related]
9. Why interferon beta 1b was licensed is a mystery. Harvey P. BMJ; 1996 Aug 03; 313(7052):297-8. PubMed ID: 8704553 [No Abstract] [Full Text] [Related]
10. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment. Blake G, Murphy S. Neurology; 1997 Dec 03; 49(6):1747-8. PubMed ID: 9409387 [No Abstract] [Full Text] [Related]
11. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Rice G. Arch Neurol; 2001 Aug 03; 58(8):1297-8. PubMed ID: 11493173 [No Abstract] [Full Text] [Related]
12. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Pachner AR. Neurology; 1997 Sep 03; 49(3):647-50. PubMed ID: 9305316 [No Abstract] [Full Text] [Related]
13. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Alsalameh S, Manger B, Kern P, Kalden J. Arthritis Rheum; 1998 Apr 03; 41(4):754. PubMed ID: 9550494 [No Abstract] [Full Text] [Related]
14. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis]. Tilbery CP, Moreira MA, Mendes MF, Lana-Peixoto MA. Arq Neuropsiquiatr; 2000 Sep 03; 58(3A):769-76. PubMed ID: 10973126 [Abstract] [Full Text] [Related]
15. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Frese A, Bethke F, Lüdemann P, Stögbauer F. Neurology; 1999 Nov 10; 53(8):1892-3. PubMed ID: 10563657 [No Abstract] [Full Text] [Related]
16. The role of interferons in the treatment of multiple sclerosis. Kelley CL. J Neurosci Nurs; 1996 Apr 10; 28(2):114-20. PubMed ID: 8718760 [Abstract] [Full Text] [Related]
17. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients. Morra VB, Coppola G, Orefice G, De Michele G, Vacca G, Filla A, Bonavita V. Neurology; 2004 Mar 09; 62(5):829-30. PubMed ID: 15007146 [No Abstract] [Full Text] [Related]